Form 4: Plus Therapeutics Insider Equity Grant Disclosure

Chief Development Officer Eric Joseph Daniels received a grant of 20,000 restricted stock units and 20,000 stock options.

Summary

• Eric Joseph Daniels, Chief Development Officer of Plus Therapeutics, Inc., was granted 20,000 Restricted Stock Units (RSUs) and 20,000 stock options on April 20, 2026.
• The RSUs represent a contingent right to receive common stock, with vesting beginning July 1, 2027.
• The stock options have an exercise price of $7.30 per share and expire on April 19, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership personnel via multi-year vesting schedules.

Negatives

• Potential for future shareholder dilution upon the exercise of options and vesting of RSUs.

Risks

• Market price volatility affecting the value of the granted equity.
• Performance-based risks associated with the company's ability to meet development milestones.

Future Outlook

The equity grants are subject to multi-year vesting schedules, indicating a long-term commitment to the company's development pipeline.

Management Comments

• The filing does not contain narrative management commentary.

Industry Context

StockSavvy.ai notes that equity grants to C-suite executives in the biotechnology sector are standard practice for aligning management incentives with long-term clinical and commercial development goals.

Comparison to Industry Standards

• The use of multi-year vesting schedules for RSUs and options is consistent with standard corporate governance practices for small-cap biotech firms.
• The 10-year expiration term for stock options is standard for executive compensation packages.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options and vesting of RSUs.

Next Steps

• Vesting of RSUs beginning July 1, 2027.
• Vesting of stock options beginning April 20, 2027.

Key Dates

Keywords

Plus Therapeutics, PSTV, Form 4, Insider Trading, Equity Compensation, Biotech